Vimarsana
Biggest News Aggregation in the World

Page 11 - Early Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Early Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Early Phase Today - Breaking & Trending Today

Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes o - Vimarsana News

Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes o

DURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes of the company’s le...

TScan Therapeutics Announces Upcoming Poster Presentation - Vimarsana News

TScan Therapeutics Announces Upcoming Poster Presentation

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

Covid-19-Leitlinie aktualisiert | PZ – Pharmazeutische Zeitung - Vimarsana News

Covid-19-Leitlinie aktualisiert | PZ – Pharmazeutische Zeitung

Die S3-Leitlinie »Empfehlungen zur stationären Therapie von Patienten mit Covid-19« wurde aktualisiert. Es gibt vor allem Änderungen ...

DGAP-News: Bit Capital GmbH: Was kommt nach dem Crypto-Crash? - Vimarsana News

DGAP-News: Bit Capital GmbH: Was kommt nach dem Crypto-Crash?

Emittent / Herausgeber: Bit Capital GmbH / Schlagwort(e): Marktbericht/Stellungnahme Bit Capital GmbH: Was kommt nach dem Crypto-Crash? 15.09.2022 / 07:55 CET/CEST Für den Inhalt

Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society - Vimarsana News

Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Society

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International...